Gunderson Thomas J. sold $722K of TMDX

Gunderson Thomas J. sold 9,624 shares of TransMedics Group, Inc. (TMDX) at $75.06 ($0.72M total) on 2026-06-15.

Original reporting
SEC EDGAR · Gunderson Thomas J.
Published Jun 17, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TMDX
Neutral
high confidence
Mentioned
$TMDX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMDXNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director, which can influence short-term sentiment but does not provide new information about TransMedics’ business, financial results, or outlook.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing lacks any fundamental catalyst.

03

What to watch

The article does not state whether the director’s remaining stake is meaningful relative to prior holdings, nor does it provide any company performance or guidance changes.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-17, transaction dated 2026-06-15

Background

The article is a SEC Form 4 insider transaction disclosure for TransMedics Group, Inc. (TMDX).

Company-level read

Ticker impact

$TMDXNeutralHigh confidence
Context

TransMedics director Thomas J. Gunderson filed a Form 4 selling 9,624 shares at $75.06 for about $722K, reducing direct holdings to 16,642.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying corporate news, guidance, or operational catalyst in the text.

Market effects

Minimal. Insider selling in a single name does not imply sector-wide changes based on the provided text.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned liquidity needs; without additional context, it may not signal reduced confidence.

Key entities

  • TransMedics Group, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Thomas J. Gunderson

    Director who sold 9,624 shares at $75.06 on 2026-06-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

TransMedics revenue up 41% to USD 203M in Q3 2026

TransMedics reported Q3 2026 revenue of $203M, up 41% YoY, driven by increased organ transplant volumes and logistics services. Gross margin was 58.5%, with operating income of $28.1M. The company cited growth catalysts like ENHANCE Heart Part B and DENOVO Lung, and plans for European expansion. Net income fell to $17.1M, or $0.46 per share, from $24.3M, or $0.66 per share, a year earlier.

$TMDXMed

TransMedics Group Q3 Earnings Call Highlights

TransMedics Group reported Q3 product gross margin at 79.2% and service gross margin at 32.2%. Adjusted net income was $18.9M, or $0.51 per share, with $493M in cash. The company completed ENHANCE Heart Part A enrollment and plans submissions in 2027. It also targets European expansion and kidney platform trials in 2027, maintaining its full-year adjusted operating margin outlook of 12.5% to 14%.